Clinical studies confirm glutathione is safe for long-term use when taken in proper doses
& Dogan, G
While all groups experienced some decline in FEV1 over 52 weeks, the 25-mg dose limited this decline to just 24 mL compared to 62 mL with placebo, a difference that reached statistical significance ( 6.1.3.3 Safety profile and tolerability Throughout the 52-week treatment period, brensocatib demonstrated a reassuring safety profile
Methods Study Setting Launched in April 2015 in collaboration with the National Psoriasis Foundation, the CorEvitas Psoriasis Registry (ClinicalTrials.gov: NCT02707341) is an independent, prospective, multicenter, non-interventional study that enrolls adults ( 18 years of age) who have been diagnosed with psoriasis, are willing and able to provide written informed consent for participation, and started on or switched to an eligible psoriasis treatment (US Food and Drug Administration [FDA]-approved biologic and non-biologic systemic therapies) at enrollment or 12 months before enrollment [12]
Also CPT analogues showed a good correlation between polarity and BCRP-association, where highly polar compounds showed substrate specificity
